K. Shakery

发表

Dimethylfumarate inhibits nuclear binding of nuclear factor κB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein β in activated human T cells

U. Mrowietz, S. Gerdes, K. Shakery, 2007, The British journal of dermatology.

Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs

W. Wigger‐Alberti, K. Shakery, Ragna Williams, 2017, Skin Pharmacology and Physiology.

Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis

K. Reich, U. Mrowietz, R. Langley, 2010 .

A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.

B. Elewski, Z. Draelos, J. Harper, 2015, Cutis.

Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial.

S. Tyring, J. Solomon, K. Shakery, 2016, Cutis.

Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial.

S. Tyring, J. Solomon, K. Shakery, 2016, Cutis.

An empirically generated responder definition for rosacea treatment

C. Gerlinger, J. Endrikat, K. Shakery, 2017, Clinical, cosmetic and investigational dermatology.

Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone®) Injection for the Treatment of Multiple Sclerosis

U. Mrowietz, K. Shakery, Noémi Soós, 2004, American journal of clinical dermatology.

[Psoriasis--clinical picture and current therapy].

K. Reich, K. Shakery, 2009, Medizinische Monatsschrift fur Pharmazeuten.

Understanding Causes of Death in Patients With Acute Respiratory Distress Syndrome: A Narrative Review

K. Shakery, P. Vora, Susan E Bromley, 2024, Critical care explorations.